Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02020785 · ClinicalTrials.gov registry record · NA
Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23
A NA study, sponsored by Geisinger Clinic.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02020785: Completed NA study, sponsored by Geisinger Clinic.
NCT02020785 is a NA study that has completed, run by Geisinger Clinic. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02020785, a NA study, has completed, sponsored by Geisinger Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Phosphorus-based food additives are commonly used by food manufacturers for many applications, such as enhancing flavor, in ready-to-eat foods and beverages. While these additives can significantly increase an individual's daily phosphorus intake, little is known about the effect of dietary phosphorus on kidney health. In this study, the investigators will first lower baseline phosphorus intake to about 1000mg/d by educating participants to avoid foods with phosphorus additives. Then, participants will be randomized to a higher phosphorus period (\~2gm/d) and a lower phosphorus period (\~1gm/d) by providing unaltered, commercially-available food/beverage products with and without phosphorus additives. The investigators hypothesize that participants will have higher urine albumin excretion and fibroblast growth factor-23 (FGF-23) during the higher phosphorus period compared to the lower phosphorus period.
Primary Outcome
Two 24-hour urine collections will be collected during the 3rd week of each period
Interventions
- OTHER Higher phosphorus period
- OTHER Lower phosphorus period
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-09 |
| Phase | NA |
What the finished NCT02020785 record still lists
NCT02020785 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Higher phosphorus period is the first listed.
NCT02020785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02020785 about?
NCT02020785 is a clinical study titled "Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23". Phosphorus-based food additives are commonly used by food manufacturers for many applications, such as enhancing flavor, in ready-to-eat foods and beverages. While these additives can significantly increase an individual's daily phosphorus intake, little is known about the effect of dietary phosphor...
What is the current status of trial NCT02020785?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2014-01. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02020785?
The interventions under investigation include: Higher phosphorus period (OTHER), Lower phosphorus period (OTHER).
Who is sponsoring clinical trial NCT02020785?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02020785's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia